[go: up one dir, main page]

SG10202102467RA - Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond - Google Patents

Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond

Info

Publication number
SG10202102467RA
SG10202102467RA SG10202102467RA SG10202102467RA SG10202102467RA SG 10202102467R A SG10202102467R A SG 10202102467RA SG 10202102467R A SG10202102467R A SG 10202102467RA SG 10202102467R A SG10202102467R A SG 10202102467RA SG 10202102467R A SG10202102467R A SG 10202102467RA
Authority
SG
Singapore
Prior art keywords
conjugating
protein
agent
methods
thiol moiety
Prior art date
Application number
SG10202102467RA
Inventor
Jayme Franklin
xin xin Lin
Jeffrey Gorrell
Timothy Tully
Matthew Hutchinson
Charity Tucker Bechtel
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG10202102467RA publication Critical patent/SG10202102467RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10202102467RA 2014-07-24 2015-07-17 Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond SG10202102467RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462028679P 2014-07-24 2014-07-24

Publications (1)

Publication Number Publication Date
SG10202102467RA true SG10202102467RA (en) 2021-04-29

Family

ID=55163580

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202102467RA SG10202102467RA (en) 2014-07-24 2015-07-17 Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond
SG11201700365TA SG11201700365TA (en) 2014-07-24 2015-07-17 Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201700365TA SG11201700365TA (en) 2014-07-24 2015-07-17 Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond

Country Status (15)

Country Link
US (2) US11370838B2 (en)
EP (1) EP3172219A4 (en)
JP (3) JP6956630B2 (en)
KR (1) KR102463267B1 (en)
CN (1) CN106536540A (en)
AR (1) AR101304A1 (en)
AU (2) AU2015294389B2 (en)
BR (1) BR112017001403A2 (en)
CA (1) CA2955007C (en)
IL (1) IL250148B2 (en)
MX (2) MX2017001022A (en)
MY (1) MY198629A (en)
RU (2) RU2744978C2 (en)
SG (2) SG10202102467RA (en)
WO (1) WO2016014360A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106536540A (en) * 2014-07-24 2017-03-22 基因泰克公司 Method for conjugating reagents to sulfhydryl moieties in proteins containing at least one trisulfide bond
EP3580234A1 (en) 2017-02-08 2019-12-18 Pfizer Inc. Large scale production process for capped and un-capped antibody cysteines and their use in therapeutic protein conjugation

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (en) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd Novel urokinase derivative, its preparation and thrombolytic agent containing the same
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2665353B2 (en) * 1988-09-10 1997-10-22 住商ファーマインターナショナル株式会社 Methods for producing bispecific antibodies
JPH0278699A (en) 1988-09-12 1990-03-19 Green Cross Corp:The Benzoylurea compound/albumin complex
JPH02218700A (en) * 1989-02-17 1990-08-31 Nippon Kayaku Co Ltd Dispecific antibody and adoptive immunity using the same antibody
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
ZA955789B (en) 1994-07-15 1996-03-11 Novo Nordisk As A method of converting a hydrophobic derivative of a polypeptide into the native form
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JPH11124395A (en) 1997-10-16 1999-05-11 Seiwa Kasei Kk Peptide containing cysteine introduced thereinto and its production
SE9802454D0 (en) 1998-07-08 1998-07-08 Pharmacia & Upjohn Ab Production of peptides
CA2374050A1 (en) 1999-05-20 2000-11-30 Scios Inc. Vascular endothelial growth factor dimers
JP2004530651A (en) 2000-10-31 2004-10-07 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド， ア ボディー コーポレイト Improved protein disaggregation and refolding using high pressure
EP2353611B1 (en) 2002-07-31 2015-05-13 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US20040048315A1 (en) 2002-08-28 2004-03-11 Pharmacia Corporation Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
EP2100619B1 (en) * 2003-02-20 2014-02-12 Seattle Genetics, Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of immune disorders
RU2356909C2 (en) * 2003-11-13 2009-05-27 Ханми Фарм. Инд. Ко., Лтд. Protein complex, obtained by using fragment of immunoglobulin, and method of such complex obtaining
EP1725586B1 (en) * 2004-03-02 2015-01-14 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
AU2005249490B2 (en) * 2004-06-01 2010-07-29 Genentech, Inc. Antibody drug conjugates and methods
ES2344120T3 (en) 2004-12-29 2010-08-18 Novo Nordisk Health Care Ag METHOD TO PREVENT TRAINING OF POLYPEPTIDE TRISULFIDE DERIVATIVES.
NZ597251A (en) * 2006-05-30 2013-08-30 Genentech Inc Antibodies and immunoconjugates and uses therefor
US20080220448A1 (en) 2006-09-01 2008-09-11 Blincko Stuart J Antigenic protein conjugates and process for preparing same
JP5394246B2 (en) 2007-03-30 2014-01-22 ジェネンテック， インコーポレイテッド Antibodies and immunoconjugates and methods for their use
CL2008001334A1 (en) * 2007-05-08 2008-09-22 Genentech Inc ANTI-MUC16 ANTIBODY DESIGNED WITH CISTEINE; CONJUGADO THAT UNDERSTANDS IT; METHOD OF PRODUCTION; PHARMACEUTICAL FORMULATION THAT UNDERSTANDS IT; AND ITS USE TO TREAT CANCER.
SG183044A1 (en) 2007-07-16 2012-08-30 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugatesand methods of use
JP5469600B2 (en) * 2007-07-16 2014-04-16 ジェネンテック， インコーポレイテッド Anti-CD79b antibody and immunoconjugate and method of use thereof
UA106586C2 (en) 2008-01-31 2014-09-25 Дженентек, Інк. Anti-cd79b antibodies and imunokonugate and methods for their use
RU2506994C2 (en) * 2008-01-31 2014-02-20 ДЖОРДЖИЯ-ПЭСИФИК КЕМИКАЛЗ ЭлЭлСи Composition of oxidised and maleated derivatives
DK2483289T4 (en) * 2009-10-02 2025-05-19 Biogen Ma Inc METHODS FOR PREVENTION AND REMOVAL OF TRISULPHIDE BONDS
DK2542576T3 (en) * 2010-03-02 2016-08-01 Seattle Genetics Inc METHODS OF SCREENING ANTIBODIES
CA2815967A1 (en) * 2010-11-05 2012-05-10 Covx Technologies Ireland Limited Anti-diabetic compounds
EP2707383B1 (en) * 2011-05-13 2018-04-18 Biogen MA Inc. Methods of preventing and removing trisulfide bonds
WO2013060867A2 (en) * 2011-10-27 2013-05-02 Genmab A/S Production of heterodimeric proteins
CA3111357A1 (en) * 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
JP6242865B2 (en) * 2012-05-01 2017-12-06 ジェネンテック， インコーポレイテッド Anti-PMEL17 antibody and immune complex
IN2014DN10428A (en) * 2012-06-19 2015-08-21 Polytherics Ltd
CN106536540A (en) * 2014-07-24 2017-03-22 基因泰克公司 Method for conjugating reagents to sulfhydryl moieties in proteins containing at least one trisulfide bond

Also Published As

Publication number Publication date
US20170209593A1 (en) 2017-07-27
JP2021046419A (en) 2021-03-25
KR20170028435A (en) 2017-03-13
IL250148B (en) 2022-11-01
CA2955007A1 (en) 2016-01-28
WO2016014360A1 (en) 2016-01-28
US20220372141A1 (en) 2022-11-24
BR112017001403A2 (en) 2017-11-21
AU2015294389B2 (en) 2021-04-29
JP2017526652A (en) 2017-09-14
EP3172219A1 (en) 2017-05-31
RU2017105428A3 (en) 2018-08-29
MX2022012589A (en) 2022-11-09
IL250148B2 (en) 2023-03-01
CA2955007C (en) 2023-04-11
RU2744978C2 (en) 2021-03-17
JP2023052645A (en) 2023-04-11
AU2015294389A1 (en) 2017-02-23
AR101304A1 (en) 2016-12-07
MY198629A (en) 2023-09-11
SG11201700365TA (en) 2017-02-27
RU2021106673A (en) 2021-11-25
IL250148A0 (en) 2017-03-30
JP7219256B2 (en) 2023-02-07
MX2017001022A (en) 2017-12-20
JP6956630B2 (en) 2021-11-02
EP3172219A4 (en) 2018-04-04
US11370838B2 (en) 2022-06-28
CN106536540A (en) 2017-03-22
AU2021209196A1 (en) 2021-08-19
AU2021209196B2 (en) 2023-02-02
RU2017105428A (en) 2018-08-29
KR102463267B1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
IL290457A (en) Antibodies and conjugates thereof
IL260074A (en) Covalent polymer-antigen particle conjugates
IL261188A (en) Antibodies to tigit
IL250819A0 (en) Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
ZA201607385B (en) Anti-ptk7 antibody-drug conjugates
HUE049622T2 (en) Highly charged antibody-drug conjugates
DK3119885T3 (en) Antibody-fynomer conjugates
GB201513607D0 (en) Pyrrolobenzodiazepine-antibody conjugates
LT3149345T (en) WAY TO COMBINE TWO OBJECTS
DK3148591T3 (en) Nanoparticle-drug conjugates
ZA201701337B (en) Conjugates and conjugating reagents
EP3355931C0 (en) PROTEIN CONJUGATES
ZA201704709B (en) Antibody-urease conjugates for therapeutic purposes
EP3359718C0 (en) Elongated composite body
GB201504694D0 (en) Covalent conjugates
IL250148B (en) Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond
GB2554027B (en) Glue compositions and methods
HK1238263A1 (en) Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond
GB201620828D0 (en) Compositions of antibody construct-agonist conjugates and methods thereof
FR3022492B1 (en) PNEUMATIC IN TWO PARTS SUITABLE FOR RECHAPING
UA29483S (en) BALL JOINT FINGER
UA29250S (en) BALL JOINT FINGER
UA26904S (en) BALL JOINT FINGER
UA29116S (en) BALL JOINT FINGER
UA29219S (en) BALL JOINT FINGER